Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma

被引:1
|
作者
Casagrande, Naike [1 ]
Borghese, Cinzia [1 ]
Aldinucci, Donatella [1 ]
机构
[1] IRCCS, Ctr Riferimento Oncol Aviano CRO, Mol Oncol Unit, I-33081 Aviano, Italy
关键词
classical Hodgkin Lymphoma; tumor microenvironment; multiplex immunohistochemistry; heterospheroids; drug response testing; stroma-mediated drug resistance; immunosuppression; tumor education; REED-STERNBERG CELLS; TUMOR-ASSOCIATED MACROPHAGES; MAST-CELLS; BRENTUXIMAB VEDOTIN; PROTECTIVE ACTIVITY; ANALYSIS REVEALS; T-LYMPHOCYTES; EXPRESSION; GROWTH; DECREASES;
D O I
10.3390/cancers14102427
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In classical Hodgkin Lymphoma (cHL), the tumor microenvironment (TME) plays an important role in tumor progression and treatment response, making its evaluation critical for determining prognosis, treatment strategies and predicting an increase in drug toxicity. Therefore, there is a need to utilize more complex systems to study the cHL-TME and its interplay with tumor cells. To evaluate new anticancer drugs and to find the mechanisms of drug resistance, this review summarizes emerging approaches for the analysis of the TME composition and to identify the state of the disease; the in vitro techniques used to determine the mechanisms involved in the building of an immunosuppressive and protective TME; new 3-dimensional (3D) models, the heterospheroids (HS), developed to mimic TME interactions. Here, we describe the present and likely future clinical applications indicated by the results of these studies and propose a classification for the in vitro culture methods used to study TME interactions in cHL. Classic Hodgkin lymphoma is characterized by a few tumor cells surrounded by a protective and immunosuppressive tumor microenvironment (TME) composed by a wide variety of noncancerous cells that are an active part of the disease. Therefore, new techniques to study the cHL-TME and new therapeutic strategies targeting specifically tumor cells, reactivating the antitumor immunity, counteracting the protective effects of the TME, were developed. Here, we describe new methods used to study the cell composition, the phenotype, and the spatial distribution of Hodgkin and Reed-Sternberg (HRS) cells and of noncancerous cells in tumor tissues. Moreover, we propose a classification, with increasing complexity, of the in vitro functional studies used to clarify the interactions leading not only to HRS cell survival, growth and drug resistance, but also to the immunosuppressive tumor education of monocytes, T lymphocytes and fibroblasts. This classification also includes new 3-dimensional (3D) models, obtained by cultivating HRS cells in extracellular matrix scaffolds or in sponge scaffolds, under non-adherent conditions with noncancerous cells to form heterospheroids (HS), implanted in developing chick eggs (ovo model). We report results obtained with these approaches and their applications in clinical setting.
引用
收藏
页数:25
相关论文
共 50 条
  • [31] Introduction - Non-Hodgkin's lymphoma: Approaches to current therapy
    Fisher, RI
    ONCOLOGY-NEW YORK, 1998, 12 (10): : 9 - 10
  • [32] Lymphangiogenesis in Classical Hodgkin Lymphoma - Preliminary Study with Clinicopathological Correlations
    Benharroch, Daniel
    Prinsloo, Isebrand
    Gopas, Jacob
    Lazarev, Irena
    JOURNAL OF CANCER, 2016, 7 (14): : 2117 - 2123
  • [33] A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
    Salehi, Matin
    Pirosa, Maria Cristina
    Bruscaggin, Alessio
    Bergamo, Lodovico Terzi Di
    Jauk, Federico
    Forestieri, Gabriela
    Bocchetta, Simone
    Piffaretti, Deborah
    Moia, Riccardo
    Cristaldi, Vanessa
    Di Trani, Martina
    Galimberti, Georgia Alice
    Pini, Katia
    Spina, Valeria
    Giordano, Claudia
    Condoluci, Adalgisa
    Annunziata, Salvatore
    Bergesio, Fabrizio
    Boldorini, Renzo
    Borsatti, Eugenio
    Bulian, Pietro
    Chauvie, Stephane
    Cuzzocrea, Marco
    Gerber, Bernhard
    Kurlapski, Michal
    Larocca, Luigi Maria
    Rinaldi, Andrea
    Rodari, Marcello
    Romanowicz, Grzegorz
    Sacchetti, Gian Mauro
    Stathis, Anastasios
    Stuessi, Georg
    Zangrilli, Ilaria
    Calabretta, Eleonora
    Corrado, Francesco
    Pinto, Antonello
    Mazzucchelli, Luca
    Gattei, Valter
    Zaucha, Jan Maciej
    Santoro, Armando
    Hohaus, Stefan
    Cavalli, Franco
    Zucca, Emanuele
    Gaidano, Gianluca
    Carlo-Stella, Carmelo
    Tzankov, Alexandar
    Ceriani, Luca
    Rossi, Davide
    BLOOD, 2024, 144
  • [34] Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma
    Kallam, Avyakta
    Armitage, James O.
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (04) : 293 - 300
  • [35] PHARMACOKINETIC APPROACHES TO STUDY OF DRUG INTERACTIONS
    LEVY, G
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1976, 281 (DEC10) : 24 - 39
  • [36] Lymphocyte depleted classical Hodgkin lymphoma: A clinical, morphologic and immunohistologic study
    Slack, G. W.
    Ferry, J. A.
    Harris, N. L.
    Gonguly, A.
    Zukerberg, L. R.
    MODERN PATHOLOGY, 2008, 21 : 274A - 275A
  • [37] Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
    Kasamon, Yvette L.
    Jacene, Heather A.
    Gocke, Christopher D.
    Swinnen, Lode J.
    Gladstone, Douglas E.
    Perkins, Brandy
    Link, Brian K.
    Popplewell, Leslie L.
    Habermann, Thomas M.
    Herman, Joseph M.
    Matsui, William H.
    Jones, Richard J.
    Ambinder, Richard F.
    BLOOD, 2012, 119 (18) : 4129 - 4132
  • [38] Drug Shortages and Curative Cancer Therapy: The Problem of Dacarbazine and Classical Hodgkin's Lymphoma
    Soriano, Nicole
    Berlin, Kate
    Gordon, Leo I.
    JCO ONCOLOGY PRACTICE, 2022, 18 (07) : 499 - +
  • [39] Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
    Johnston, Patrick B.
    Pinter-Brown, Lauren C.
    Warsi, Ghulam
    White, Kristen
    Ramchandren, Radhakrishnan
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [40] Lymphocyte depleted classical Hodgkin lymphoma: A clinical, morphologic and immunohistologic study
    Slack, G. W.
    Ferry, J. A.
    Harris, N. L.
    Ganguly, A.
    Zukerberg, L. R.
    LABORATORY INVESTIGATION, 2008, 88 : 274A - 275A